Reshma Kewalramani is the CEO of Vertex Pharmaceuticals, having taken on the role in April 2020 after previously serving as the Chief Medical Officer. She has made significant impacts in the biotech industry, particularly known for her work on medicines...
Reshma Kewalramani is the CEO of Vertex Pharmaceuticals, having taken on the role in April 2020 after previously serving as the Chief Medical Officer. She has made significant impacts in the biotech industry, particularly known for her work on medicines that treat cystic fibrosis. Under her leadership, Vertex has expanded its portfolio significantly, developing innovative therapies that have changed the lives of many patients. In 2022, her total compensation was around $15.86 million, which included a salary of $1.39 million and a substantial amount in stock awards, showing her commitment to the company's success. Kewalramani’s personal stock holdings have also grown impressively, valued at over $71 million by 2024, hinting at her strong belief in what Vertex can achieve. Her strategy focuses on delivering transformative medicines that target serious diseases, and she has a background in medicine that shapes her approach to leadership at Vertex.